Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Dr. Stephen  Dale M.D.

Chief Medical Officer

Ms. Teresa Brophy Bair Esq., J.D.

Chief Legal Officer & Corporate Secretary

Mr. Thomas  Doyle

Senior Vice President of Finance & Accounting

Ms. Maureen  Clancy M.B.A.

Vice President and Global Head of Program Leadership & Project Management

Dr. Troy Edward Wilson J.D., Ph.D.

Chairman, Chief Executive Officer & President

Mr. Pete  De Spain

Executive Vice President of Investor Relations & Corporate Communications

Mr. Brian T. Powl M.B.A., M.S.

Chief Commercial Officer

Dr. Roger  Bakale Ph.D.

Senior Vice President of Manufacturing & Supply Chain

Dr. Mollie  Leoni M.D.

Executive Vice President of Clinical Development

Ms. Kathleen  Ford

Chief Operating Officer

Biotehnoloģija

Kura Oncology, Inc.

Kura Oncology, Inc. Vadības struktūra

Informācija par vadību